Announcement on the board resolution at Annual General Meeting 2018

Amendment on the announcement for 2018 Annual General Meeting (discussion notes)
May 16, 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC)
July 8, 2018
  1. Date of the shareholders’ meeting: Jun 27, 2018
  2. Important resolutions (1) profit distribution/deficit compensation: the 2017 earning distribution and expense appropriation was recognized
  3. Important resolutions (2) amendments of the company charter: none
  4. Important resolutions (3) business report and financial statements: the 2017 Annual report and financial report was recognized
  5. Important resolutions (4) elections of board of directors and supervisors: none
  6. Important resolutions (5) other proposals: resolved shareholders to authorize the board of directors to handle cash increase of common shares to issue overseas via private placement
  7. Any other matters that need to be specified: none